Related Experiment Videos
Pentobarbital desensitization in a 3-month-old child
Manish J Butte1, Brenda Dodson, Anahita Dioun
1Division of Immunology, Children's Hospital Boston, Boston, Massachusetts, USA.
Allergy and Asthma Proceedings
|October 30, 2004
Summary
This case study details the first reported protocol for pentobarbital desensitization in a 3-month-old infant with refractory seizures and phenobarbital sensitivity. The successful intravenous desensitization offers a new therapeutic option for similar challenging cases.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Immunology
Background:
- Barbiturates, like phenobarbital, are essential antiepileptic and sedative drugs.
- Immune-mediated adverse reactions, including anticonvulsant hypersensitivity syndrome, can limit their use.
- Phenobarbital sensitivity presents a significant challenge in managing refractory epilepsy.
Observation:
- A 3-month-old infant with refractory generalized convulsive status epilepticus required pentobarbital therapy due to phenobarbital sensitivity.
- Standard skin tests for pentobarbital and phenobarbital were negative.
- The infant underwent intravenous pentobarbital desensitization in the intensive care unit.
Findings:
- Intravenous pentobarbital desensitization was successfully performed without any adverse reactions.
- This procedure enabled the continued use of pentobarbital for seizure control in a highly sensitive patient.
- Negative skin tests did not predict the absence of hypersensitivity, necessitating desensitization.
Implications:
- This case establishes the first reported protocol for pentobarbital desensitization.
- This desensitization protocol may offer a viable alternative for managing refractory seizures in patients with barbiturate hypersensitivity.
- Further research is warranted to explore the safety and efficacy of barbiturate desensitization in pediatric populations.